Stockscreener 앱 받기
30.05
10.28%
2.80
시간 외 거래:
30.05
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% HigherHere's What Happened - MarketBeat
Enliven Therapeutics stock hits 52-week high at $30.98 - Investing.com
Enliven Therapeutics stock hits 52-week high at $30.98 By Investing.com - Investing.com UK
(ELVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Enliven Therapeutics, Inc. $ELVN Shares Bought by HighVista Strategies LLC - MarketBeat
Energy Moves: Should I trade or invest in Enliven Therapeutics IncEarnings Recap Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Enliven Therapeutics (ELVN) CMO sells 40,000 shares after option exercise - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 10,000 Shares of Stock - MarketBeat
CFO of Enliven (NASDAQ: ELVN) sells 10,000 common shares - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Enliven Therapeutics (ELVN) Form 144: Director sales total 45,000 shares - Stock Titan
Smart Money: Is Enliven Therapeutics Inc a speculative investment2025 Technical Overview & Consistent Income Trade Recommendations - baoquankhu1.vn
TD Asset Management Inc Sells 39,388 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
(ELVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
VIX Spike: Will Enliven Therapeutics Inc benefit from rising consumer demandQuarterly Portfolio Report & Accurate Buy Signal Notifications - baoquankhu1.vn
[144] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
Enliven Therapeutics stock hits 52-week high at 30.29 USD - Investing.com Nigeria
Enliven Therapeutics (ELVN) Projected to Post Earnings on Thursday - MarketBeat
Enliven Therapeutics stock hits 52-week high at 30.29 USD By Investing.com - Investing.com Canada
Enliven Therapeutics has cash runway into 2029 - BizWest
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year HighTime to Buy? - MarketBeat
ELVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Enliven Therapeutics Q4 Loss Widens - marketscreener.com
Enliven Therapeutics (stock code: ELVN) recently released its financial report for the fourth quarter and full year of fiscal 2025, while also updating the market on the company's latest business developments. - Bitget
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) advances ELVN-001 toward pivotal CML trial - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) touts ELVN-001 data and $462.6M cash runway - Stock Titan
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - PR Newswire
ELVN: ELVN-001 shows strong efficacy in CML, with pivotal data and phase 3 launch expected in 2024 - TradingView
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - mx.advfn.com
Enliven Therapeutics: Q4 Earnings Insights - Benzinga
Head-To-Head Review: ProPhase Labs (NASDAQ:PRPH) & Enliven Therapeutics (NASDAQ:ELVN) - Defense World
ELVN SEC FilingsEnliven Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen - MarketBeat
ELVN Should I Buy - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 37.94% Upside Potential in Biotech - DirectorsTalk Interviews
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Finviz
Insider Trends: Can Enliven Therapeutics Inc disrupt its industryJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Biotech fireside chat: Enliven Therapeutics at TD Cowen event - Stock Titan
(ELVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Gem with 58% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock - MarketBeat
Heyman, Enliven Therapeutics director, sells $32k in stock By Investing.com - Investing.com Canada
Plan-based 1,230-share sale by Enliven (ELVN) director disclosed - Stock Titan
Investment Report: Is SAIL forming a double bottomInsider Buying & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Catalysts: Is Enliven Therapeutics Inc a speculative investment2025 Institutional Moves & Verified Entry Point Detection - baoquankhu1.vn
Gains Report: Is First Internet Bancorp showing insider buyingJuly 2025 Action & High Conviction Investment Ideas - baoquankhu1.vn
Enliven Therapeutics (NASDAQ: ELVN) seller files 75,000-share resale with Jefferies - Stock Titan
Stock Market Recap: How sensitive is Enliven Therapeutics Inc to inflationJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 14.1% in January - MarketBeat
Can Enliven Therapeutics Inc disrupt its industryQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Enliven Therapeutics (ELVN) CFO granted 150,000 options and 25,000 RSUs - Stock Titan
Will Enliven Therapeutics Inc. benefit from rising consumer demandJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What drives Enliven Therapeutics Inc.’s stock priceJuly 2025 Breakouts & Growth Focused Stock Reports - mfd.ru
Is Enliven Therapeutics Inc. stock attractive for income investorsProduct Launch & Daily Stock Trend Watchlist - mfd.ru
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
History Review: Can Enliven Therapeutics Inc disrupt its industryWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):